U.S. Markets closed

Idera Pharmaceuticals begins Phase 2 trial of IMO-8400 psoriasis candidate

Idera Pharmaceuticals has initiated dosing in a randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in patients with moderate to severe plaque psoriasis. IMO-8400, an antagonist of the Toll-like receptors 7, 8, and 9, is a lead clinical candidate in Idera’s autoimmune disease program. In a Phase 1 trial involving single escalating doses and multiple doses, IMO-8400 was well tolerated and inhibited TLRs 7, 8, and 9-mediated immune responses. Data from the Phase 1 study will be presented at a scientific meeting in June.